175 related articles for article (PubMed ID: 34893510)
41. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.
Hua Y; White-Gilbertson S; Kellner J; Rachidi S; Usmani SZ; Chiosis G; Depinho R; Li Z; Liu B
Clin Cancer Res; 2013 Nov; 19(22):6242-51. PubMed ID: 24077352
[TBL] [Abstract][Full Text] [Related]
42. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
[TBL] [Abstract][Full Text] [Related]
43. HJURP inhibits proliferation of ovarian cancer cells by regulating CENP-A/CENP-N.
Zhang Y; Zhang W; Sun L; Yue Y; Shen D; Tian B; Du M; Dong M; Liu Y; Zhang D
Bull Cancer; 2022 Oct; 109(10):1007-1016. PubMed ID: 35940943
[TBL] [Abstract][Full Text] [Related]
44. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
[TBL] [Abstract][Full Text] [Related]
45. Holliday junction recognition protein promotes pancreatic cancer growth and metastasis via modulation of the MDM2/p53 signaling.
Wang CJ; Li X; Shi P; Ding HY; Liu YP; Li T; Lin PP; Wang YS; Zhang GQ; Cao Y
Cell Death Dis; 2020 May; 11(5):386. PubMed ID: 32439850
[TBL] [Abstract][Full Text] [Related]
46. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
47. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
48. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
49. Holliday junction‑recognition protein modulates apoptosis, cell cycle arrest and reactive oxygen species stress in human renal cell carcinoma.
Yuan JS; Chen ZS; Wang K; Zhang ZL
Oncol Rep; 2020 Sep; 44(3):1246-1254. PubMed ID: 32582972
[TBL] [Abstract][Full Text] [Related]
50. AIMP1 promotes multiple myeloma malignancy through interacting with ANP32A to mediate histone H3 acetylation.
Wei R; Zhu Y; Zhang Y; Zhao W; Yu X; Wang L; Gu C; Gu X; Yang Y
Cancer Commun (Lond); 2022 Nov; 42(11):1185-1206. PubMed ID: 36042007
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
[TBL] [Abstract][Full Text] [Related]
52. HJURP knockdown disrupts clonogenic capacity and increases radiation-induced cell death of glioblastoma cells.
Serafim RB; Cardoso C; Di Cristofaro LFM; Pienna Soares C; Araújo Silva W; Espreafico EM; Paçó-Larson ML; Price BD; Valente V
Cancer Gene Ther; 2020 May; 27(5):319-329. PubMed ID: 31138900
[TBL] [Abstract][Full Text] [Related]
53. Analysis of methylation pattern in multiple myeloma.
San-Miguel J; García-Sanz R; López-Pérez R
Acta Haematol; 2005; 114 Suppl 1():23-6. PubMed ID: 16166769
[TBL] [Abstract][Full Text] [Related]
54. Mitotic regulator Mis18β interacts with and specifies the centromeric assembly of molecular chaperone holliday junction recognition protein (HJURP).
Wang J; Liu X; Dou Z; Chen L; Jiang H; Fu C; Fu G; Liu D; Zhang J; Zhu T; Fang J; Zang J; Cheng J; Teng M; Ding X; Yao X
J Biol Chem; 2014 Mar; 289(12):8326-36. PubMed ID: 24519934
[TBL] [Abstract][Full Text] [Related]
55. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
56. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.
Nardiello T; Jungbluth AA; Mei A; Diliberto M; Huang X; Dabrowski A; Andrade VC; Wasserstrum R; Ely S; Niesvizky R; Pearse R; Coleman M; Jayabalan DS; Bhardwaj N; Old LJ; Chen-Kiang S; Cho HJ
Clin Cancer Res; 2011 Jul; 17(13):4309-19. PubMed ID: 21565982
[TBL] [Abstract][Full Text] [Related]
57. Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation.
Krieger S; Grunau C; Sabbah M; Sola B
Exp Hematol; 2005 Jun; 33(6):652-9. PubMed ID: 15911089
[TBL] [Abstract][Full Text] [Related]
58. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
Croonquist PA; Van Ness B
Oncogene; 2005 Sep; 24(41):6269-80. PubMed ID: 16007202
[TBL] [Abstract][Full Text] [Related]
59. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
[TBL] [Abstract][Full Text] [Related]
60. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
Zhang G; Miao F; Liu K; Wu J; Xu J
Technol Cancer Res Treat; 2021; 20():15330338211034270. PubMed ID: 34269120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
